Caplacizumab
Caplacizumab (INN) is a humanized monoclonal that binds to VWF.[1]
References
- ↑ World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 106" (PDF). WHO Drug Information 25 (4).
Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems |
|---|
| | Bone ("-os-", "-s(o)-") | Human ("-osu-") | |
|---|
| Humanized ("-sozu-") | |
|---|
|
|---|
| | Musculoskeletal ("-mul-") | |
|---|
| | Circulatory ("-c(i[r])-") | Human ("-ciru-") | |
|---|
| Mouse ("-ciro-") | |
|---|
| Chimeric ("-cixi-") | |
|---|
| | |
|---|
|
|---|
| | Neurologic ("-ne(u)(r)-") | Human ("-neru-") | |
|---|
| Humanized ("-nezu-"/"-neuzu-") | |
|---|
|
|---|
| | Angiogenesis inhibitor ("-anibi-") | |
|---|
| |
|